Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ: VCYT )

30.43 -0.53 (-1.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 605,828
Open 31.03
Bid (Size) 30.43 (18)
Ask (Size) 30.45 (5)
Prev. Close 30.96
Today's Range 30.15 - 31.05
52wk Range 18.61 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill

Performance

YTD
-24.75%
-24.75%
1 Month
-27.43%
-27.43%
3 Month
-30.06%
-30.06%
6 Month
+0.36%
+0.36%
1 Year
+36.34%
+36.34%

More News

Read More
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
Via Benzinga
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Via Benzinga
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
Via Chartmill
Demystifying Veracyte: Insights From 7 Analyst Reviews
Via Benzinga
Exploring NASDAQ:VCYT's high growth characteristics.
Via Chartmill
Earnings Scheduled For February 24, 2025
Via Benzinga
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?
Via Chartmill
Navigating 9 Analyst Ratings For Veracyte
Via Benzinga
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
Via Chartmill
Breaking Down Veracyte: 4 Analysts Share Their Views
Via Benzinga
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
From Veracyte
Via Business Wire
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Veracyte Announces Third Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
From Veracyte, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.